Hutchison China Meditech Limited Change of Directors (2544U)
16 January 2017 - 10:48AM
UK Regulatory
TIDMHCM
RNS Number : 2544U
Hutchison China Meditech Limited
16 January 2017
Change of Directors
London: Monday, January 16, 2017: Hutchison China MediTech
Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces with effect
from February 1, 2017, Mr Paul Rutherford Carter has been appointed
as Senior Independent Non-Executive Director and member of the
Audit Committee, Remuneration Committee and Technical Committee of
Chi-Med; and Mr Shigeru Endo tendered his resignation as
Non-executive Director and Mr Christopher Nash tendered his
resignation as Senior Independent Non-executive Director and member
of Audit Committee and Remuneration Committee effective on the same
date.
Mr Carter, aged 56, has more than 25 years of experience in the
pharmaceutical industry. From 2006 to 2016, Mr Carter served in
various senior executive roles at Gilead Sciences, Inc. ("Gilead"),
a research-based biopharmaceutical company, with the last position
as Executive Vice President, Commercial Operations. In this role Mr
Carter headed the worldwide commercial organisation responsible for
the launch and commercialisation of all of Gilead's products. Prior
to joining Gilead, he spent 14 years with GlaxoSmithKline PLC (GSK)
and its group companies, with the last position as a Regional Head
of the International business in Asia.
Mr Carter is currently a director of Alder Biopharmaceuticals,
Inc. He was previously a director of Gilead Sciences Ltd, Gilead
Sciences International Ltd. and Gilead Sciences Europe Ltd. within
the past five years.
Mr Carter holds a degree in Business Studies from the Ealing
School of Business and Management (now merged into University of
West London) and is a Fellow of the Chartered Institute of
Management Accountants in the UK.
He does not have any shareholdings in Chi-Med. Save for the
information disclosed above, there is no other information in
relation to Mr Carter that is required to be disclosed pursuant to
Rule 17 and Schedule 2(g) of the AIM Rules for Companies.
Mr Simon To, Chairman of Chi-Med said "We thank Mr Shigeru Endo
and Mr Christopher Nash for their invaluable contributions to the
Company during their tenure and welcome Mr Carter to the Board
whose experience in the global biopharmaceutical industry will be
important to the Company."
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which
researches, develops, manufactures and sells pharmaceuticals and
healthcare products. Its Innovation Platform, Hutchison MediPharma
Limited, focuses on discovering and developing innovative
therapeutics in oncology and autoimmune diseases for the global
market. Its Commercial Platform manufactures, markets, and
distributes prescription drugs and consumer health products in
China.
Chi-Med is majority owned by the multinational conglomerate CK
Hutchison Holdings Limited (SEHK: 0001). For more information,
please visit: www.chi-med.com.
Forward-Looking Statements
This announcement contains forward-looking statements within the
meaning of the "safe harbor" provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These forward-looking
statements reflect Chi-Med's current expectations regarding future
events. Forward-looking statements involve risks and uncertainties.
Such risks and uncertainties include, among other things, the risk
that current or future appointees to Chi-Med's board of directors
are not effective in their respective positions, the difficulty in
locating and recruiting suitable candidates for its board of
directors and the management difficulties which may arise from
changes in Chi-Med's board of directors. Existing and prospective
investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof.
For further discussion of these and other risks, see Chi-Med's
filings with the U.S. Securities and Exchange Commission and on
AIM. Chi-Med undertakes no obligation to update or revise the
information contained in this announcement, whether as a result of
new information, future events or circumstances or otherwise.
Contacts
Investor Enquiries
Christian Hogg, CEO +852 2121 8200
International Media Enquiries
Anthony Carlisle, +44 7973 611 888 (Mobile) anthony.carlisle@cdrconsultancy.co.uk
Citigate Dewe Rogerson
U.S. Based Media Enquiries
Brad Miles, BMC Communications +1 (917) 570 7340 (Mobile) bmiles@bmccommunications.com
Susan Duffy, BMC Communications +1 (917) 499 8887 (Mobile) sduffy@bmccommunications.com
Investor Relations
Matt Beck, The Trout Group +1 (917) 415 1750 (Mobile) mbeck@troutgroup.com
David Dible, +44 7967 566 919 (Mobile) david.dible@citigatedr.co.uk
Citigate Dewe Rogerson
Panmure Gordon (UK) Limited
Richard Gray / Andrew Potts +44 (20) 7886 2500
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAEAEFKFLSXEFF
(END) Dow Jones Newswires
January 16, 2017 05:48 ET (10:48 GMT)